Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 6.83%
As of Monday, July 13, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 6.83%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Commentary & Analysis
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.30%
As of Friday, July 10, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 5.30%, which has investors questioning if this is right time to buy.Michael Rose
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Up 7.36%
As of Thursday, July 02, Voyager Therapeutics, Inc.’s VYGR share price has surged by 7.36%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.66%
As of Friday, June 05, Voyager Therapeutics, Inc.’s VYGR share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Up 5.45%
As of Friday, May 22, Voyager Therapeutics, Inc.’s VYGR share price has surged by 5.45%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $189.1 | $251.9 | 27% |
|
| Shares Out (Mil) | 59.5 | 50.8 | 52% |
|
| Institutional Ownership | 97.4% | 92.0% | 74% |
|
| Float (Mil) | 44.2 | 40.5 | 45% |
|
| Beta | 1.26 | 0.95 | 74% |
|
| Avg Daily Volume (000s) | 645 | 447 | 63% |
|
| Price Change (52-week) |
(2.2%) | 54.2% | 44% |
|
| Growth | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (25.1%) | 14.0% | 2% |
|
| Net Income (5yr) | (39.4%) | (9.8%) | 9% |
|
| EPS (5yr) | (32.5%) | 16.3% | 7 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.2%) | (15.6%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 8 | 9 | |
| Current EPS | ($0.508) | ($1.657) | ($1.560) | |
| Month Ago EPS | ($0.508) | ($1.657) | ($1.560) | |
| # Rev Up | 2 | 1 | 0 | |
| # Rev Down | 0 | 1 | 2 | |
| Three Months Ago EPS | ($0.479) | ($1.774) | ($1.712) | |
| Year/Year Chg | 8.1% | (18.8%) | (36.8%) | |
| Financials | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $37 | $39 | 17% |
|
| Net Income (TTM) (Mil) | ($117) | ($43) | 10% |
|
| EPS (TTM) | ($1.978) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($128) | ($30) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($32) | $3 | 23% |
|
| Long-Term Debt (Q1) (Mil) | $27 | $5 | 34% |
|
| Enterprise Value (Q1) (Mil) | $108 | $182 | 21% |
|
| Valuation | VYGR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.09 | 2.60 | 26% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | VYGR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (243.5%) | 63.8% | 1% |
|
| Net Margin | (319.6%) | (64.7%) | 3% |
|
| ROA | (40.7%) | (49.7%) | 14% |
|
| ROE | (52.3%) | (55.4%) | 15% |
|
| Liabilities to Assets | 20.8% | 30.3% | 13% |
|
| F-Score | 1 | 3 | 1% |
|
Voyager Therapeutics, Inc. did not pass any screens on 7/30/2026.
